Drugs / Mayzent
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MAYZENT | — | 2022-03-01 | fda.gov ↗ |
| Approved | EU (EMA) | Mayzent | — | 2020-01-13 | europa.eu ↗ |
| Approved | US (FDA) | MAYZENT | — | 2019-03-26 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04925557 Comparator | Nov 2021 → Jun 2023 | secondary progressive multiple sclerosis | State University of New York at Buffalo | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mayzent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04925557 ↗ |